Gastroparesis (GP) is a gastric motility disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. This expert consensus covers aspects of GP etiology (diabetes, surgery, drug-induced, idiopathic, scleroderma, etc.), symptomatology, diagnosis (scintigraphic imaging, ultrasound contrast meal assessment, and radiopaque marker gastric motility testing), and treatment (pharmacological therapy, nutritional support, traditional Chinese medicine, and interventions targeting the pylorus, such as endoscopic surgery and surgical procedures). GP significantly impacts patients' psychological well-being and quality of life, potentially leading to psychological disorders such as anxiety and depression, and also imposes a heavy economic burden on patients and society. Therefore, this expert consensus advocates for the establishment of a multidisciplinary team diagnosis and treatment model, which will further standardize and optimize the diagnosis and treatment process of GP in our country and is crucial for improving patients' therapeutic outcomes and quality of life.

Background: Borderline dyslipidemia is a prevalent cardiovascular risk factor for which pharmacological intervention is not always indicated. Omega-3 polyunsaturated fatty acids and coenzyme Q10 (CoQ10)  have been reported to influence lipid metabolism and oxidative status; however, their combined effects in individuals with borderline dyslipidemia remain unclear. Objective: This study aimed to explore the associations of combined supplementation with α-linolenic acid (ALA) and CoQ10 with lipid metabolism, gut microbiota, and serum metabolites in patients with borderline dyslipidemia. Methods: In a 12-week, single-center randomized, open-label controlled trial, 90 participants with borderline dyslipidemia were assigned to receive either ALA (1.6 g/d) plus CoQ10 (136 mg/d) or standard dietary and exercise guidance alone. Primary outcomes included changes in serum lipids, lipoprotein subfractions (by NMR spectroscopy), gut microbiota (16S rRNA sequencing), and serum metabolomic profiles. Results:  Eighty-two participants completed the trial. Compared with the control group, the Omega-3_Q10 group showed significantly different change-from-baseline values in multiple lipid parameters, with mixed directions of change. Exploratory analyses identified concurrent changes in selected lipoprotein subfractions, gut microbiota composition, bile acid-related metabolites, and antioxidant markers. Conclusions:  Combined supplementation with ALA and CoQ10 was associated with short-term changes in lipid-related and metabolic markers in individuals with borderline dyslipidemia. Given the exploratory nature of the analyses, short intervention duration, and absence of clinical cardiovascular endpoints, the long-term clinical implications of these findings remain uncertain and warrant confirmation in larger, prospective studies with defined clinical outcomes.